SCHEMBL5454885

SCHEMBL5454885

Cn1c(=O)[nH]c(=O)c2nc(-c3ccc(F)cc3)c(Cl)nc21

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRDT Q58F21 1/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42
TP53 P04637 1/20 0.40
KDM1A O60341 1/20 0.39
IDO1 P14902 1/20 0.39
TSHR P16473 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
HSD17B10 Q99714 1/20 0.38
THRB P10828 1/20 0.38
FYN P06241 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5434638 0.90 MEN1 (0.47) POLBKDM4EGAAALDH1A1GLA
SCHEMBL5434556 0.88 ALDH1A1 (0.44) POLBSMN1; SMN2KDM4EGAAALDH1A1
SCHEMBL5434692 0.87 KDM4E (0.56) POLBSMN1; SMN2KDM4EGAAALDH1A1
SCHEMBL5437609 0.85 KDM4E (0.47) SMN1; SMN2KDM4EGAAALDH1A1GLA
SCHEMBL5446598 0.85 BRDT (0.41) BRDTPOLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL5437075 0.84 KDM4E (0.41) KDM4EGAAALDH1A1GLAHPGD
SCHEMBL5435513 0.80 PDE4A (0.42) POLBSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL5446767 0.77 KMT2A (0.45) POLBSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL5435686 0.76 XDH (0.45) KDM4EGAAALDH1A1GLAHPGD
SCHEMBL6320759 0.75 KDM4E (0.48) POLBSMN1; SMN2KDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US claimed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP claimed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO claimed
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US disclosed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 BRDT 353/4885POLB 2845/4885SMN1; SMN2 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.